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Abstract: Introduction: Treatment options for neuroendocrine tumors (NETs) are rarely curative,
as NETs frequently show resistance to medical therapy. The use of everolimus, an mTOR inhibitor,
is limited by the development of resistance, probably due to the activation of Akt signaling. In this
context, the antidiabetic drug metformin is able to inhibit mTOR, providing a rationale for the use of
metformin and everolimus in combination. Methods: We investigated the effects of the metformin
and everolimus combination on NET cell proliferation, apoptosis, colony formation, cell viability,
NET spheroids growth and the involvement of the Akt and mTOR pathways, and also developed
everolimus-resistant NET cells to further study this combination. Results: Metformin and everolimus
in combination are more effective than monotherapy in inhibiting pancreatic NET (PAN-NET) cell
proliferation (−71% ± 13%, p < 0.0001 vs. basal), whereas no additive effects were observed on
pulmonary neuroendocrine tumor (PNT) cell proliferation. The combinatorial treatment is more
effective than monotherapy in inhibiting colony formation, cell viability, NET spheroids growth rate
and mTOR phosphorylation in both NET cell lines. In a PAN-NET cell line, metformin did not affect
Akt phosphorylation; conversely, it significantly decreased Akt phosphorylation in a PNT cell line.
Using everolimus-resistant NET cells, we confirmed that metformin maintained its effects, acting by
two different pathways: Akt-dependent or independent, depending on the cell type, with both
leading to mTOR suppression. Conclusions: Considering the promising effects of the everolimus and
metformin combination in NET cells, our results provide a rationale for its use in NET patients.
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1. Introduction
Neuroendocrine tumors (NETs) are considered a rare malignancy. However, their incidence
has rapidly increased in the last decades. NETs are more frequently localized in the gastrointestinal
tract (60–70%) and in the lungs (20–30%). The only treatment that offers a cure is surgery. However,
up to 50% of patients are diagnosed with metastatic disease, and curative surgery is usually not an
option [1,2]. These patients can be offered long-term systemic treatment, for both symptomatic relief
and tumor growth suppression. Treatment options include somatostatin analogs, the mTOR inhibitor
everolimus, the tyrosine kinase inhibitor sunitinib and peptide receptor radionuclide therapy, alone or
combined with cytoreductive procedures. Unfortunately, a significant number of NET patients do not
respond to the above-mentioned medical treatments and the molecular mechanisms involved are still
not clearly understood [3–5].
The demonstration of the important role of the PI3K-Akt-mTOR pathway in pancreatic NET
(PAN-NET) tumorigenesis [6] and the finding of an abnormal activation of mTOR—a serine/threonine
protein kinase—in patients with PAN-NET [7] led to the use of the mTOR inhibitor everolimus for the
treatment of pulmonary neuroendocrine tumors (PNTs) and PAN-NETs [8,9]. Unfortunately, the use
of everolimus is limited by the development of resistance, which has been reported both in vivo
and in vitro [9,10]. The mechanisms leading to resistance are not well understood, but activation
of a negative feedback leading to the activation of Akt and the consequent mTOR reactivation has
been proposed as a possible resistance mechanism. In particular, mTOR inhibition induced insulin
receptor substrate 1 (IRS-1) expression and abrogated feedback inhibition of the pathway, leading to
Akt activation in cancer cell lines and in primary cell cultures [11]. Indeed, hyperactivation of PI3K/Akt
may contribute to PAN-NET development and behavior [6].
Combination therapy to ablate mTOR function and prevent Akt activation may improve antitumor
activity. Indeed, the combination of everolimus and a PIK3 inhibitor (LY29400) inhibited the
overexpression of pAkt, decreased cell growth in PAN-NET cell lines (BON cell line) and progression
of liver metastasis in vivo [12]. However, Akt/PI3K inhibitors may have a limited clinical role because
of unacceptable toxicity in patients [13,14].
Interestingly, the use of metformin (1.1-dimethylbiguanide hydrochloride), a widely used
antidiabetic drug, was associated with significantly lower risks of cancer incidence and mortality [15].
It displays potent anticancer properties in different types of cancers [16–19], being able to suppress
mammalian target of rapamycin (mTOR).
Although the most well-known mechanism of metformin action is adenosine
monophosphate-activated protein kinase (AMPK) activation, recent investigations have shown
that AMPK-independent pathways can explain some of metformin’s beneficial metabolic effects
(i.e., suppression of glucagon signaling, activation of autophagy, attenuation of inflammasome
activation) [20]. In this respect, a significant association between metformin use and longer
PFS (progression-free survival) in patients affected by advanced PAN-NETs [21] has been found.
Recently, we demonstrated the efficacy of metformin in inhibiting pancreatic neuroendocrine
tumor cell line (QGP-1) proliferation in a dose- and time-dependent manner. Moreover,
metformin exerted its anticancer effects, inhibiting mTOR phosphorylation through AIP (aryl
hydrocarbon receptor-interacting protein) modulation in QGP-1 cells [22].
Importantly, metformin stimulates phosphorylation of IRS-1, which transmits signals from the
insulin and IGF-1 receptors to the PI3K–Akt pathway, leading to inhibition of IGF-1–insulin signaling.
This activity itself has the potential to downregulate mTOR signaling [23]. Therefore, metformin,
by inhibiting mTOR and blocking the IGFR-1/IRS-1/PI3K/Akt cascade, may have a role in overcoming
everolimus resistance, suggesting a rationale for the use of metformin in combination with everolimus.
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Although previous studies have demonstrated the anticancer properties of metformin, the impact
of metformin in everolimus-resistant NET cells and the effects of metformin and everolimus in
combination in NET cells are unknown.
The aims of this study are to evaluate the anticancer effects of the metformin and everolimus
combination, the molecular mechanism involved in its action in pancreatic and pulmonary NET cells
and the effect of metformin on everolimus-resistant NET cells.
2. Results
2.1. The Effect of Metformin and Everolimus on NET Cell Proliferation and Apoptosis
First, by performing cell proliferation assays, we evaluated the antiproliferative effects of metformin
and everolimus, alone or in combination, on cultured cells obtained from surgically removed human
NETs. As shown in Figure 1A,B, metformin and everolimus alone decreased cell proliferation in
PAN-NETs (−44% ± 6%, p < 0.01 vs. basal and −35% ± 9%, p < 0.01 vs. basal, respectively) and PNTs
(−70% ± 12%, p < 0.0001 vs. basal and −32% ± 3%, p < 0.01 vs. basal, respectively). Interestingly,
in combination they were more effective than each monotherapy in inhibiting primary PAN-NET cell
proliferation (−71% ± 13%, p < 0.0001 vs. basal, p < 0.05 vs. metformin and p < 0.01 vs. everolimus)
(Figure 1A and Figure S1). On the contrary, the metformin and everolimus combination was not more
effective than the single drugs on inhibiting cell proliferation in primary PNT cells (Figure 1B).
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Figure 1. The effect of metformin (Met) and everolimus (Eve) on neuroendocrine tumor (NET) cell 
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Figure 1. The eff ct of metfor i ( et) and verolimus (Eve) on neuroe docrine tumor (NET)
cell prolife and apoptosis. (A,B) To measure cell proliferation, we incubated primary NET
cells with metfor in 10 mM and everolimus 10 nM, alone or in combination, for 24 h, then with
BrdU for 24 h. Experiments were repeated 3 times and each determination was done in triplicate.
Basal = untreated control.
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Values represent mean (± SD.) ** = p < 0.01, **** = p < 0.0001 vs. corresponding basal,
# = p < 0.05, ## = p < 0.01 vs. single drug. Statistical analysis was performed with a one-way
ANOVA followed by Tukey’s post-hoc test. (C,D) To measure cell proliferation, QGP-1 and
H727 cell lines were incubated for 24 h with metformin (1–10 mM) and everolimus (10–100
nM), alone or in combination, and then treated with BrdU for 2 h. Experiments were repeated
at least 4 times and each determination was done in triplicate. Values represent mean (±SD.)
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 vs. corresponding basal, ## = p < 0.01 vs.
metformin, ◦ = p < 0.05 vs. everolimus. (E,F) The graph shows the percentage of apoptotic cells after
metformin (10 mM) and everolimus (10 nM) treatment, alone or in combination, compared to basal.
Only metformin 10 mM significantly increased the rate of apoptosis. Values represent mean ± SD of 3
experiments. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 vs. corresponding basal. Statistical analysis was
performed with a one-way ANOVA test followed by Dunnett’s post-hoc test.
Thereafter, considering the low availability of NET tumor samples and the low yield in terms of
viable cells from sample dispersion, to further elucidate the antiproliferative action of the metformin
and everolimus combination, we used the QGP-1 and H727 cell lines as a model for PAN-NET s and
PNTs, respectively.
As demonstrated in primary NETs, we confirmed that the metformin and everolimus combination
was more effective than the monotherapies in inhibiting QGP-1 cell proliferation, with the greatest
effect achieved using metformin at 10 mM and everolimus at 10 nM (−77% ± 13%, p < 0.0001 vs. basal,
p < 0.01 vs. metformin and p < 0.05 vs. everolimus) (Figure 1C). Similarly, as shown in Figure 1D,
both metformin and everolimus as monotherapies decreased H727 cell proliferation (−40% ± 5% at
10mM, p < 0.0001 vs. basal and −29% ± 7% at 10 nM, p < 0.001 vs. basal, respectively), but the
combination was not more effective in inhibiting H727 cell growth.
To investigate the ability of metformin and everolimus to induce apoptosis, QGP-1 and H727 cells
were incubated with either drug alone or in combination and analyzed by flow cytometry. As shown
in Figure 1E,F, only metformin significantly increased QGP-1 and H727 cell apoptosis (233% ± 40%,
p < 0.001 vs. basal; 192% ± 26%, p < 0.01 vs. basal; everolimus: 117% ± 36%, p = 0.85 vs. basal;
120% ± 6%, p = 0.62 vs. basal), while no additive effect was detected by everolimus co-incubation
(187% ± 16%, p < 0.01 vs. basal; 157% ± 20%, p < 0.05 vs. basal).
2.2. The Effect of Metformin and Everolimus on QGP-1 and H727 Cell Viability
To investigate the antiproliferative effect of the metformin and everolimus combination after a
longer incubation period, studies on cell viability were conducted in QGP-1 and H727 cells, using an
MTT assay. Since the longer incubation time allowed the use of lower concentrations of metformin
(100 µM or 400 µM), as recently demonstrated in QGP-1 cells [22], cells were treated with metformin
(50 µM, 100 µM or 400 µM) and everolimus 10 nM, alone or in combination, and incubated for seven
days. The incubation with either metformin (100 µM and 400 µM) or everolimus induced a significant
reduction of cell viability in both cell lines (Figure 2). The combination of metformin 400 µM and
everolimus 10 nM was significantly more effective than each monotherapy in reducing cell viability of
both QGP-1 and H727 cells (−68% ± 9% and −61% ± 7%, p < 0.0001 vs. basal, respectively).
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Figure 2. The effect of metformin (Met) and everolimus (Eve) on QGP-1 and H727 cell viability. (A,B)
Cells were incubated with metformin (50 µM, 100 µM and 400 µM), or treated with everolimus (10 nM),
or with the combination of everolimus 10 nM and metformin (50 µM, 100 µM and 400 µM) for 7 days.
The combination of metformin 400 µM and everolimus 10 nM induced a more effective reduction of both
cell lines’ viability than each monotherapy. Values represent mean (± SD.) * = p < 0.05, **** = p < 0.0001
vs. corresponding basal, # = p < 0.05 and #### = p < 0.0001 vs. everolimus, ◦ = p < 0.05 and
◦◦ = p < 0.01 vs. metformin. Experiments were repeated at least 3 times and each determination was
done in triplicate. Statistical analysis was performed with a one-way ANOVA test followed by Tukey’s
post-hoc test.
2.3. Metformin and Everolimus in Combination Are More Effective than Each Monotherapy in Inhibiting
QGP-1 and H727 Colony Formation
To determine the role of the combination of metformin and everolimus in the ability of QGP-1 and
H727 t grow in vitro and t orm colonies, cells were incubated with either drug alone or with their
combination for seven days. As shown in Figure 3A,B, in QGP-1 cells, metformin an everolimus alone
signifi antly decreased the quantity of colonies, number of cells (−33% ± 13%, p < 0.01 metformin at
100 µM, −46% ± 13%, p < 0.001 metformin at 400 µM, −48% ± 22% everolimus at 10 nM, p < 0.0001)
and colony size (Figure 3C) with respect to untreated cells. The combination of metformin 400 µM and
everolimus 10 nM was m re effective than each monotherapy (number of cells −73% ± 10%, p < 0.0001
vs. basal).
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Figure 3. The effect of metformin (Met) and everolimus (Eve) on QGP-1 and H727 colony formation.
(A,D) QGP-1 and H727 cells incubated with or without metformin 400 µM, everolimus 10 nM or
with their combination. Microscopy images show that the combination of metformin and everolimus
strongly decreased QGP-1 and H727 cell number and colony size. Scale bar 100 µm. (B,E) To count the
number of cells, after metformin treatment (100 µM and 400 µM) and everolimus (10 nM), alone or
in combinatio , for 7 days, QGP-1 and H727 cells were incubated with the CyQUANT® GR dye and
fluorescence was me ur d at 480/52 nm. The graph shows that the in and everolimus
combination is more effective than each monotherap i t e number of QGP-1 and H 27
cells. Values represent mean ± SD of at least 3 experiments. * = p < p 0. 01 * = p < . 001
vs. corresponding basal, ◦ = p < 0. 5 and ◦◦◦ = p i ti s. metformin, # = p < .05 the
combination vs. ev rolimus. Statistical analysis as ith a one-way ANOVA test followed
by Tukey’s post-hoc test. (C,F) To measure colony surf ce re , fiel s ere randomly selected in
each well. Average of colony area (µm2) was measured using the soft are I ageJ. Experiments were
repeated at least 3 times. Values represent mean (±SD.) **** = p < 0.0001 vs. corresponding basal,
◦ = p < 0.05 vs. metformin, ## = p < 0.01 vs. everolimus. Statistical analysis was performed with a
one-way ANOVA test followed by Tukey’s post-hoc test. Scale bar of (A) Scale bar 100 µm.
In H727 cell lines, metformin and everolimus alone significantly reduced the quantity of colonies,
number of cells (−34% ± 15%, p < 0.001 metformin at 400 µM, −48% ± 7% everolimus at 10 nM,
p < 0.0001) and colony size (Figure 3D–F) with respect to untreated cells. The combination of
metformin 400 µM and everolimus 10 nM was more effective than each monotherapy (number of cells
−70% ± 4% p < 0.0001), suggesting that the combination requires a longer incubation time in H727
cells to be effective in suppressing cell proliferation.
2.4. Metformin and Everolimus Treatment on QGP-1 and H727 3D Spheroids
Since the combination of metformin and everolimus has shown a promising additive
antiproliferative effect in QGP-1 and H727 monolayers, we tested the effect of these compounds
on the growth of QGP-1 and H727 3D spheroids. We observed the growth rate of spheroids after zero,
three and six days of treatment (T0, T3, T6).
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As shown in Figure 4, in untreated conditions, the size of QGP-1 and H727 spheroids increased
in a time-dependent manner (T6: +59% ± 18% and +88% ± 25%, p < 0.05 and p < 0.0001 vs. T0,
respectively). After six days of treatment with metformin or everolimus alone, in both QGP-1 and H727
3D models, the growth rate was significantly blocked with respect to the untreated control (in QGP-1:
−17% ± 7% and −19% ± 1%, p < 0.05 and p < 0,01 vs. T6 basal; in H727: −20% ± 4% and −21% ± 1%,
p < 0,0001 vs. T6 basal, respectively). Interestingly, the combination of metformin and everolimus
induced a more potent effect on the growth rate of QGP-1 and H727 spheroids than monotherapy
(−33% ± 12% and −35% ± 16%, p < 0,01 and p < 0,0001 vs. T6 basal, respectively).
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observed with the combination treatment (Figure 5A,B). These data suggest that the combination of 
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Figure 4. Metformin (Met) and everolimus (Eve) treatment on QGP-1 and H727 3D Spheroids. QGP-1
And H727 spheroids were performed using the BIOMIMESYS® hydroscaffold of crosslinked hyaluronic
acid (HA) chains. Cells were followed by imaging using brightfield microscopy with a 4X objective
lens (Widefield IX53 Inverted, Olympus). (A,C) Representative images of QGP-1 and H727 spheroids
after their formation and after three and six days of treatment with metformin 400 µM and everolimus
(10nM), alone or in combination. 0 days: time point when treatments started (T0); 3 days and 6 days
are the time points analyzed after the treatments started (T3–T6). Scale bar 100 µm. (B,D) Growth of
the 3D spheroids upon treatment with metformin and everolimus, alone or in combination. The area
was measured using the software ImageJ. Experiments were repeated 2 times and each determination
done in triplicate. Statistical analysis was performed with a two-way ANOVA test followed by Tukey’s
post-hoc test. Values represent mean (±SD.) and are shown as a percentage of control at day 0.
* = p < 0.05, ** = p <0.01, **** = p < 0.0001 vs. T6 Basal. ◦ = p < 0.05 vs. T0 Basal, ◦◦◦◦ = p < 0.0001 vs.
T0 Basal.
2.5. The Effect of Metformin and Everolimus on mTOR and Akt Phosphorylation in NET Cells
Considering that everolimus is a mTOR inhibitor and metformin may be able to block the
IGFR-1/IRS-1/PI3K/Akt/mTOR cascade, we analyzed the effects of the combination of the two
drugs on the phosphorylation of mTOR to better understand the mechanism by which it exerts
its anticancer activity.
As expected, metformin and everolimus alone decreased the levels of p-mTOR in both QGP-1
and H727 cell lines. Compared with each monotherapy, a significant reduction of p-mTOR levels was
observed with the combination treatment (Figure 5A,B). These data suggest that the combination of
metformin and everolimus induces a more potent mTOR blockade in both NET cell lines.
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Figure 5. The effect of metformin (Met) and everolimus (Eve) on mTOR and Akt phosphorylation in
QGP-1 and H727 cells. (A,B) Representative immunoblots of phospho-mTOR demonstrating that the
inhibition of mTOR by metformin and everolimus in combination is more potent than each monotherapy
in both cell lines. The graph shows the quantification of phospho-mTOR normalized to the housekeeping
gene vinculin (mean value ± SD from 3 independent experiments). *** = p < 0.001, **** = p < 0.0001
vs. corresponding basal and # = p < 0.05, ### = p < 0.001 vs. the single drug. Statistical analysis
was performed with a one-way ANOVA test followed by Tukey’s post-hoc test. (C) Representative
immunoblots of phospho-Akt demonstrating that metformin does not affect Akt phosphorylation in the
QGP-1 cell line. The graph shows the quantification of phospho-Akt normalized to the housekeeping
gene GAPDH (mean value ± SD from 3 independent experiments). Statistical analysis was performed
with a one-way ANOVA test followed by Tukey’s post-hoc test. (D) Representative immunoblots
of phospho-Akt demonstrating that metformin significantly decreases Akt phosphorylation in H727
cell lines. The graph shows the quantification of phospho-Akt normalized to the housekeeping gene
GAPDH (mean value ± SD from 3 independent experiments). * = p < 0.05 vs. corresponding basal.
Statistical analysis was performed with a one-way ANOVA test followed by Dunnett’s post-hoc test.
Unprocessed images for WB results see Figures S2 and S3.
In order to investigate the mechanism responsible for the anticancer activity of the metformin
and everolimus combination in NET cells, the effect of the two drugs on the phosphorylation of Akt
was assessed by Western blot analysis. As shown in Figure 5C, metformin and everolimus alone or in
combinati n did not exert any significant effect on Akt ph sphorylation in QGP-1 cells. On the c ntrary,
metformin significantly decreas d the l vels of p-Akt in H727 cell li es (Figure 5D), suggesti g Akt
involv ment in etformin action in H727 cells.
2.6. The Effects of Metformin In Everolimus-Resistant QGP-1-R and H727-R
In order to study the molecular mechanism involved in everolimus resistance and to assess a
novel therapeutic strategy, we induced resistance to everolimus in QGP-1 and H727 cell lines. After the
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establishment of the long term everolimus resistance, QGP-1-R and H727-R were treated with metformin
and everolimus, alone or in combination, to perform cell proliferation assays. As expected, everolimus
did not decrease QGP-1-R and H727-R cell proliferation, whereas metformin (10 mM) inhibited
QGP-1-R and H727-R cell proliferation (−32% ± 10%, p < 0.0001 vs. basal, −36% ± 10%, p < 0.001 vs.
basal, respectively) and this effect was maintained when the cells were incubated with the combination
of metformin (10 mM) and everolimus (10 nM) (−31% ± 8%, p < 0.001 vs. basal, −25% ± 8%, p < 0.05 vs.
basal, respectively), as shown in Figure 6A,B. To confirm these results, QGP-1-R and H727-R cells were
incubated with either drug alone or with their combination and their effects on cell cycle were analyzed
by flow cytometry. As shown in Figure 6C,D, metformin (10 mM) inhibited the growth of QGP-1-R
and H727-R cells by blocking cell cycle progression at the G0/G1 phase and this effect was not affected
when metformin and everolimus were used in combination. Interestingly, metformin kept promoting
apoptosis in everolimus-resistant NET cells, alone (+155% ± 21%, p < 0.001 vs. basal in QGP-1-R and
+117% ± 11%, p < 0.001 vs. basal in H727-R) or in combination with everolimus (+105% ± 13%, p < 0.01
vs. basal in QGP-1-R and +129% ± 10%, p < 0.001 vs. basal in H727-R) (Figure 6E,F).
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Figure 6. Metformin (Met) continued to exert its anticancer effects on cell proliferation, cell cycle
and apoptosis in QGP-1-R and H727-R cells. (A,B) To measure cell proliferation, everolimus-resistant
QGP-1-R and H727R cell were treated with metformin (1–10 mM) and everolimus (Eve 10–100 nM) or
their combination for 24 h and then with BrdU for 2 h. Experiments were repeated 3 times and each
determination was done in triplicate.
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Values represent mean (± SD.) * = p < 0.05, *** = p < 0.001, **** = p < 0.0001 vs. corresponding basal.
(C,D) QGP-1-R and H727-R cells were treated with metformin (10 mM) and everolimus (10 nM) or their
combination for 24 h and their cell cycle was analyzed by flow cytometry. Experiments were repeated
at least 3 times. Values represent mean (± SD.) * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001
vs. corresponding basal. Statistical analysis was performed with a one-way ANOVA test followed
by Dunnett’s post-hoc test. (E,F) The graph showed the percentage of apoptotic cells after metformin
(10 mM) and everolimus (10 nM) treatment, alone or in combination, compared to basal in QGP-1-R
and H727-R cells. Only metformin 10 mM significantly promoted apoptosis. Values represent mean ±
SD of 3 experiments. ** = p < 0.01, *** = p < 0.001 vs. corresponding basal. Statistical analysis was
performed with a one-way ANOVA test followed by Dunnett’s post-hoc test.
Moreover, in order to investigate the pathway activated by metformin in everolimus-resistant
NET cells, we tested the effects of metformin and everolimus on mTOR phosphorylation. As expected,
everolimus did not decrease mTOR phosphorylation in QGP-1-R and H727-R, while metformin was
still able to decrease mTOR phosphorylation (−66% ± 21%, p < 0.05 vs. basal and −41 ± 10%, p < 0.05
vs. basal, respectively) (Figure 7A,B).
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Figure 7. The effect of metformin (Met) on mTOR and Akt phosphorylation in QGP-1-R and H727-R
cells. (A,B) Representative immunoblots of phospho-mTOR demonstrating that metformin continued
to inhibit mTOR phosphorylation in everolimus-resistant QGP-1-R and H727-R cells. Graphs show the
quantification of phospho-mTOR normalized to the housekeeping gene vinculin (mean value ± SD from
3 independent experiments). * = p < 0.05 vs. corresponding basal. Statistical analysis was performed
with a one-way ANOVA test followed by Dunnett’s post-hoc test. (C,D) Representative immunoblots
of p-Akt, after metformin and everolimus incubation, alone or in combination. Metformin did not
affect Akt phosphorylation in QGP-1-R cells, conversely, significantly decreased p-Akt in H727-R cells.
Graphs show the ratio of p-Akt/GAPDH normalized to basal (mean value ± SD from 3 independent
experiments). * = p < 0.05, ** = p < 0.01 vs. corresponding basal. Statistical analysis was performed
with a one-way ANOVA test followed by Dunnett’s post-hoc test. Unprocessed images for WB results
see Figures S4 and S5.
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Finally, we analyzed the effects of metformin and everolimus on Akt phosphorylation in QGP-1-R
and H727-R. As shown in Figure 7C,D, everolimus increased Akt phosphorylation in both resistant
cell lines (+116% ± 45%, p < 0.01 vs. basal in QGP-1-R, +50% ± 1%, p < 0.01 vs. basal in H727-R),
suggesting the involvement of the Akt pathway in everolimus resistance. Metformin did not affect Akt
phosphorylation in QGP-1-R cells, though it significantly decreased Akt phosphorylation in H727-R
cells, confirming the data shown in sensitive QGP-1 and H727 cells.
3. Discussion
Currently available treatment options for advanced NETs are rarely curative. Consequently,
new treatment strategies are needed. In particular, the inhibitor of the mammalian target of rapamycin
(mTOR), everolimus, is recommended by the European Neuroendocrine Tumor Society (ENETS)
guidelines for progressive, G1/G2 PAN-NETs [24]. Unfortunately, the development of drug resistance
limits its efficacy [8]. The mechanisms leading to resistance are not well understood, but the activation
of the Akt pathway seems to be involved [11]. Considering that the most potent anticancer effect
of metformin is the suppression of mTOR pathway, a key player in the regulation of cell-growth,
metabolism and survival [25], we investigated the effects of the metformin and everolimus combination.
According to several studies showing an anticancer effect of metformin in vitro and since the complete
medium of NET cells contains high amounts of growth factors and glucose that could affect metformin
action [26], we first tested the effect of metformin at millimolar ranges of concentration.
We first focused on primary NET cells, but, considering their low viability after a prolonged time
of treatment with metformin, we used it for a relatively short incubation time and at high concentration
(10 mM) in combination with everolimus at 10 nM. We demonstrated that metformin and everolimus
alone showed antiproliferative effects on both PAN-NET and PNT primary cells. The two compounds
in combination were more effective than each monotherapy only on PAN-NET cell proliferation,
whereas no additive effects on PNT cells were shown. We confirmed the results obtained on primary
cell proliferation in the corresponding cell lines, QGP-1 and H727.
We speculated that the combination might need a prolonged time of incubation to exert a more
efficacious antineoplastic effect on pulmonary NET cells. In this respect, a recent study on human
glioblastoma stem cells demonstrated that the efficacy of metformin as an anticancer agent is not
only dependent on its concentration, but also on the duration of treatment [27]. Indeed, we recently
demonstrated that metformin has dose- and time-dependent effects on QGP-1 cells. In particular,
metformin at 100 µM and 400 µM was significantly able to exert antiproliferative effects on QGP-1 cell
lines at a prolonged time of incubation [22]. In this respect, Vacante et al. considered metformin 400 µM
to be comparable to the human therapeutic dose in hepatocellular carcinoma cells [28]. Interestingly,
after a prolonged time of incubation, metformin and everolimus in combination were more effective
than each agent alone in inhibiting cell viability and the ability of both QGP-1 and H727 cells to form
colonies, a crucial event involved in tumorigenesis.
Since NET 3D spheroids mimic the in vivo NET xenograft tumor geometrically and molecularly
when compared to monolayer 2D cells [29], and 3D cell culture is becoming an efficient method for drug
screening [30], we investigated the impact of metformin and everolimus, alone and in combination, on
the growth of QGP-1 and H727 spheroids. Interestingly, metformin and everolimus treatment alone
was able to block the growth rate of QGP-1 and H727 3D spheroids, with the combination becoming
even more potent in abolishing the spheroids’ growth.
These results confirm that combinatory treatment may actually display greater efficacy than the
single monotherapies in both pancreatic and pulmonary NET models and support a potential clinical
application of the metformin and everolimus combination. In particular, given the indolent behavior
that characterizes most well-differentiated neuroendocrine tumors, chronic treatment with everolimus
in combination with metformin at therapeutic doses is likely to provide benefits in terms of tumor
growth, without significant additional toxic effects, as metformin is generally well-tolerated [28].
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We examined whether the antineoplastic effect of metformin and everolimus is mediated by the
induction of apoptosis. Metformin induced a significant increase in QGP-1 and H727 cell apoptosis,
as already demonstrated in pancreatic cancer [31] and melanoma cells [32], but no effect on apoptosis
was observed when NET cells were treated with everolimus.
We speculated that the combination of metformin and everolimus may induce a more potent mTOR
blockade, potentially counteracting the resistance mechanisms induced by everolimus. Consistently
with these observations, metformin and everolimus decreased mTOR phosphorylation in QGP-1 and
H727 cells and their combination was more effective than monotherapy.
Overactivation of PI3K/Akt has been documented in multiple cancer types, including different
NETs [33–35]. In fact, Akt plays a key role in many cellular processes [36], such as apoptosis,
cell migration and proliferation, as well as glucose metabolism. Therefore, to deepen the understanding
of the molecular mechanism involved in the anticancer action of metformin and everolimus,
we evaluated Akt phosphorylation. We demonstrated that in QGP-1 cells metformin did not affect Akt
phosphorylation, suggesting the involvement of a different pathway in mediating its effects. In this
respect, it is noteworthy that metformin acts via AIP to inhibit mTOR phosphorylation in QGP-1
cells [22]. We speculated that the more potent effect of the combination of metformin plus everolimus
in inhibiting cell proliferation, colony formation and mTOR phosphorylation in QGP-1 cell lines was
due to the action of the AIP pathway, which is involved in cell growth [22].
On the contrary, we demonstrated that metformin significantly decreased Akt phosphorylation in
H727 cells and it was also able to suppress Akt phosphorylation when combined with everolimus.
To clarify the role of metformin in the context of everolimus resistance and to confirm the mechanism
involved in the anticancer action of the metformin and everolimus combination, we developed
everolimus-resistant QGP-1-R and H727-R cells. As expected, everolimus did not affect cell proliferation
in QGP-1-R and H727-R, whereas metformin kept inhibiting cell proliferation and inducing apoptosis
in both everolimus-resistant cell lines. Importantly, metformin was still able to decrease mTOR
phosphorylation in both QGP-1-R and H727-R. These data suggest the use of metformin as a potential
therapeutic option for NET patients resistant to everolimus treatment.
Thereafter, we showed the involvement of p-Akt in the mechanism of resistance induced
by everolimus, which significantly increased Akt phosphorylation in QGP-1-R and H727-R cells.
This aspect is in line with the hypothesis that mTOR inhibition by everolimus induces a feedback loop,
leading to Akt activation and consequent mTOR reactivation [37].
Metformin did not affect Akt phosphorylation in QGP-1-R cells, though it was able to reverse
everolimus-induced Akt phosphorylation in H727-R cells. These data confirm the involvement of two
different pathways leading to mTOR suppression.
In line with what was shown in breast cancer, in which metformin and everolimus have synergistic
anticancer effects [38], this study demonstrated that the combination therapy is more effective than the
single monotherapies on the inhibition of pancreatic NET cell proliferation, and in counteracting the
formation of colonies and inhibiting mTOR phosphorylation in both pancreatic and pulmonary NET
cells. Interestingly, the combination of the two compounds displays augmented anticancer activity
through the involvement of two different pathways: Akt-independent in the QGP-1 cell line (Figure 8A)
and Akt-dependent in the H727 cell line (Figure 8B).
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Figure 8. Schematic representation of the possible mechanism of action of metformin and everolimus
in QGP-1 and H727 cells. Metformin acts via 5′-AMP-activated protein kinase (AMPK) dependent
or independent pathways, leading to mTORC1 complex inhibition. Everolimus inhibits mTOR
phosphorylation, but its long-term use is limited by the development of resistance, probably due to
the activation of Akt signaling. The combination of metformin and everolimus induces a more potent
blockade of mTOR and potentially counteracts the resistance mechanisms triggered by everolimus. (A) In
QGP-1 cells metformin did not affect Akt phosphorylation, probably acting through the AIP pathway
to decrease mTOR phosphorylation. (B) In H727 cells, metformin decreases Akt phosphorylation to
suppress mTOR phosphorylation.
We recently demonstrated that AIP silencing abrogated metformin’s modulation of AIP partners’
expression—AHR, Zac1 and HSP70—providing a plausible mechanistic role of AIP as a regulator
of the AIP-AHR-Zac1-HSP70 complex in PAN-NETs [22]. Interestingly, the transcription factor
ZAC1 is one of the targets of glycogen synthase kinase 3b (GSK3β) [39]. This kinase regulates the
expression of genes involved in cell cycle control and, as reported by Prada et al., its over-activation,
combined with decreased baseline IRS-1 protein levels, may be a crucial feature of everolimus
resistance [40]. Moreover, previous studies demonstrated that the anticancer action of metformin is
mediated by the GSK3 protein [16]. Thus, we can speculate the potential involvement of GSK3 in
mediating the Akt-independent mechanism of everolimus-induced resistance shown in QGP-1 cells.
Because of the promising effects of the everolimus and metformin combination in NET cells
and spheroids, our results provide a rationale for its use in NET patients. Moreover, the efficacy of
metformin as an antineoplastic agent in everolimus-resistant NET cells suggests its promising clinical
application as an alternative to everolimus in patients who show resistance to everolimus treatment.
4. Materials and Methods
4.1. Neuroendocrine Tumor Cell Cultures
The study was approved by the Independent Ethics Committee of Istituto Clinico Humanitas
(IRCCS), Rozzano (Milan, Italy), and conformed to the ethical guidelines of the Declaration of
Helsinki (no. 1937, 6 February, 2018). Informed consent was obtained from all subjects involved
in the study. Human neuroendocrine cells were obtained from 3 PNTs and 3 PAN-NETs (Table S1),
And characterized as previously reported [20]. Briefly, NET tissues were enzymatically dissociated
in DMEM containing 2 mg/mL collagenase (Sigma–Aldrich Corporate Headquarters, St. Louis, MO,
USA) at 37 ◦C for 2 h [41,42]. After that, a cell strainer was used, with a strong nylon mesh with 100 µm
micron pores designed for isolating primary cells to consistently obtain a uniform single cell suspension
from tissues. Dispersed cells were cultured in DMEM supplemented with 10% fetal bovine serum,
2 mM glutamine and antibiotics. Human pancreatic endocrine QGP-1 cell line (Carcinoembryonic
antigen (CEA)-producing human pancreatic islet cell carcinoma, JCRB0183, Japanese Homo Sapiens)
and H727 cell line (human typical bronchial carcinoid cell line) were grown in RPMI 1640 medium
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supplemented with 10% FBS, 2 mM glutamine and antibiotics. Cell lines were cultured at 37 ◦C in 5%
CO2 atmosphere. QGP-1 and H727 cell lines were authenticated by BMR Genomics srl (Padova, Italy),
according to Cell ID TM System (Promega, Madison, WI, USA) protocol and using Genemapper ID Ver
3.2.1, to identify DNA Short Tandem Repeat (STR) profiles.
4.2. Development of Everolimus-Resistant QGP-1 and H727 Cell Lines
QGP-1 and H727 cell lines were treated for 24 weeks with 10 nM everolimus.
Medium supplemented with 10 nM everolimus was changed every 3 days. Two independent
everolimus-resistant QGP-1 and H727 cell lines were established (R and R2). All experiments
shown were performed using QGP-1-R and H727-R; R2 cell lines were used to confirm the results.
No morphological changes were seen between QGP-1 and H727 cells and QGP-1R and H727-R cell lines.
4.3. Proliferation Assay
Cell proliferation was assessed by colorimetric measurement of 5-bromo-2′-deoxyuridine (BrdU)
incorporation during DNA synthesis in proliferating cells, according to the manufacturer’s instructions,
as previously reported [43]. Briefly, after 24 h serum starvation, cells were incubated with metformin
(1 mM, 10 mM) (#1396309, Sigma Aldrich Corporate Headquarters, St. Louis, MO, USA), or treated with
everolimus (10 nM, 100 nM), or with the combination of everolimus 10 nM or 100 nM and metformin
1 mM or 10 mM for 24 h. Afterwards, the cells were incubated with BrdU for 2 h (cell lines) and 24 h
(primary cultures) to allow BrdU incorporation in newly synthesized cellular DNA. All experiments
were repeated at least three times and each determination was done in triplicate.
4.4. Apoptosis Analysis by Flow Cytometry
Detection of apoptosis was performed using the Annexin V/PI kit (#640932, Biolegend, San Diego,
CA, USA), according to the manufacturer’s protocols. After 48 h of metformin incubation (10 mM) or
everolimus (10 nM), alone or in combination, cells were double-stained with fluorochrome-labeled
annexin V and red-fluorescent propidium iodide dye. The percentage of apoptotic cells was determined
by flow cytometry using Fluorescence-activated cell sorting _(FACS)LSRFortessa (BD Biosciences,
Franklin Lakes, NJ, USA). The results were analyzed using FACSDiva software (BD Biosciences).
4.5. Cell Viability Assay
Cell viability was assessed in QGP-1 and H727 cells by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO, USA) conversion into
formazan by mitochondrial enzymes, thus determining the number of metabolically active cells.
Cells were seeded at a cell density of 5 × 104 cells/well in 96-well plates at 37 ◦C. Cells were incubated
with metformin (50 µM, 100 µM and 400 µM), or treated with everolimus (10 nM), or with the
combination of everolimus 10 nM and metformin (50 µM, 100 µM and 400 µM) for 7 days. MTT was
dissolved in sterile phosphate-buffered saline (PBS) at 5 mg/mL and 10 µL of the obtained solution
was added to each well for a final concentration of 0.5 mg/mL, followed by incubation at 37 ◦C for
4 h to form purple-colored formazan crystals. Subsequently, the MTT solution was removed and the
cells/crystals were solubilized by adding 10% SDS solution in 0.01 M HCl overnight in a humidified
5% CO2 incubator. Absorbance was read at 570 nm in a 96-well plate in a Synergy H4 plate reader.
Each determination was done in triplicate. Experiments were repeated at least three times.
4.6. Colony Formation
QGP-1 or H727 cells were seeded into 24-well plates and 96-well plates in triplicate at a density
of 1250 cells or 500 cells, respectively. Then, cultured cells were incubated at 37 ◦C for 7 days with
metformin (100 µM and 400 µM) and everolimus 10 nM, alone or in combination. To count the
number of cells, cells were incubated with the CyQUANT® GR dye/cell-lysis buffer, according to
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the manufacturer’s protocols (#C7026, Invitrogen, Waltham, MA, USA). Number of cells were then
quantified by using a fluorescence microplate reader. Images of QGP-1 and H727 clones were acquired
using brightfield microscopy with a 4X objective lens (Widefield IX53 Inverted, Olympus, Tokyo,
Japan). Average colony area was measured using the NIH software ImageJ.
4.7. 3D Cultures (Spheroids) and Growth Measurement
For sphere formation, a suspension of QGP-1 or H727 cells was inoculated in Biomimesys®
(Celenys, Rouen, France), following the manufacturer’s instructions. Briefly, 50,000 QGP-1 or H727
cells were plated in 3D culture—96-well plates containing a hyaluronic acid matrix. When the 3D
spheroids reached around 100–200 µm in diameter at day 4, they were treated with metformin (400 µM)
and everolimus 10 nM, alone or in combination. This is denoted as day 0 for drug treatment.
Photographs of spheroids were acquired at days 0, 3 and 6, using brightfield microscopy with a
4X objective lens (Widefield IX53 Inverted, Olympus). Images were calibrated, using µm as the unit for
calculation. The area of the spheroids was determined using the ImageJ software and values are shown
as a percentage of control at day 0, as recently reported [44]. Experiments were done in triplicate and
repeated two times.
4.8. Cell Cycle Analysis
Cells were cultured in 6-well plates (6 × 105 cells per well) with 1 mL of medium. After 24 h of
metformin 10 mM and everolimus 10 nM incubation, QGP-1-R and H727-R cells were harvested and
washed twice in PBS 1× at 4 ◦C. Then cells were fixed in 1mL of cold 80% ethanol added dropwise
to the pellet while vortexing and incubated at 4 ◦C for 30 min. After that, the cells were centrifuged
at 2000 rpm for 5 min to remove ethanol and then washed twice in PBS 1× at 4◦ C. Finally, the cells
were stained for 30 min in DAPI solution (PBS, 0.01% TRITON X-100, 1 ug/mL DAPI-Invitrogen™) at
room temperature (RT) and then DNA content was read using BD FACSymphony A5. The results
were analyzed using FlowJo® software (FlowJo LLC, Ashland, OR, USA).
4.9. Immunoblot Detection of Phospho-mTOR and Phospho-Akt
To detect mTOR and Akt phosphorylation, QGP-1 and H727 cells were treated for 24 h with or
without 10 mM metformin and 10 nM everolimus, alone or in combination. Immunoblotting analysis
was performed with 1:1000 dilution of phospho-mTOR antibody and 1:1000 dilution of phospho-Akt
ser473 antibody (#2971, Cell Signaling Technology, Danvers, MA, #MAB-94111 Immunological Sciences,
Rome, Italy). Monoclonal anti-GAPDH (AM4300, Ambion, 1:4000) or anti-vinculin (1:1000 dilution,
Cell Signaling Technology, Danvers, MA, USA) were used as housekeeping genes, developed using an
anti-mouse or anti rabbit HRP-linked antibody (#7076, Cell Signaling Technology 1:2000 and #7074,
Cell Signaling Technology, 1:2000, respectively).
4.10. Statistical Analysis
The results were expressed as the mean ± SD. A paired two-tailed Student’s test was used to
detect the significance between two series of data.
One-way ANOVA analysis was used to compare three or more groups, followed by Tukey’s
multiple comparisons test. Dunnett’s method was used to test two or more experimental groups
against a single control group. For spheroid size analysis, a two-way ANOVA followed by Tukey’s
multiple comparisons test was used. Calculations were performed using GraphPad Prism 8.0 software
(GraphPad Software, Inc., La Jolla, CA, USA). p < 0.05 was accepted as statistically significant.
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5. Conclusions
Considering the promising effects of the everolimus and metformin combination in NET cells and
spheroids, our results provide a rationale for its use in NET patients. In addition, the antiproliferative
and proapoptotic effect of metformin in everolimus-resistant NET cells suggests its promising clinical
application in patients resistant to everolimus treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2143/s1,
Figure S1: Cell proliferation of three individual PA-NETs, Figures S2–S5: Unprocessed images for WB results,
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